Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Takeda Pharmaceutical (TKPHF) Interest Expenses (2017 - 2025)

Historic Interest Expenses for Takeda Pharmaceutical (TKPHF) over the last 9 years, with Q4 2025 value amounting to -$803.2 million.

  • Takeda Pharmaceutical's Interest Expenses fell 15760.68% to -$803.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$4.1 billion, marking a year-over-year decrease of 54294.09%. This contributed to the annual value of $1.4 billion for FY2025, which is 953.92% down from last year.
  • As of Q4 2025, Takeda Pharmaceutical's Interest Expenses stood at -$803.2 million, which was down 15760.68% from -$2.1 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's 5-year Interest Expenses high stood at $4.0 billion for Q1 2021, and its period low was -$2.1 billion during Q3 2025.
  • Its 5-year average for Interest Expenses is -$49.3 million, with a median of -$421.6 million in 2022.
  • Per our database at Business Quant, Takeda Pharmaceutical's Interest Expenses surged by 73931.77% in 2024 and then plummeted by 15760.68% in 2025.
  • Takeda Pharmaceutical's Interest Expenses (Quarter) stood at -$410.9 million in 2021, then tumbled by 37.38% to -$564.5 million in 2022, then soared by 50.62% to -$278.7 million in 2023, then fell by 11.86% to -$311.8 million in 2024, then tumbled by 157.61% to -$803.2 million in 2025.
  • Its Interest Expenses stands at -$803.2 million for Q4 2025, versus -$2.1 billion for Q3 2025 and -$556.3 million for Q2 2025.